TB-500 – Research Grade Thymosin Beta-4 Fragment (17–23) (10 mg)
TB-500 is a synthetic peptide corresponding to a specific
fragment of Thymosin Beta-4, commonly identified as the 17–23 amino acid
sequence. Supplied as a research-grade compound, TB-500 is intended
exclusively for use in controlled laboratory and in-vitro research
environments focused on peptide signaling behavior, molecular interaction
analysis, and cytoskeletal research models under strictly non-clinical
scientific conditions.
In experimental research settings, TB-500 is examined in laboratory systems
designed to study peptide-mediated cellular signaling, actin-related
interaction models, and molecular response behavior. Due to its defined
fragment structure, it is distinguished from full-length Thymosin Beta-4
and is utilized only in non-clinical research contexts.
TB-500 supplied for research applications is intended exclusively for
laboratory research, analytical testing, and in-vitro scientific
investigation. This compound is not intended for human or animal use and is
not approved for therapeutic, diagnostic, cosmetic, or medical applications.
For research use only. Not for human or animal consumption.
Chemical & Peptide Information
| Peptide Name | TB-500 |
| Peptide Classification | Synthetic Thymosin Beta-4 Fragment (17–23) |
| Amino Acid Length | 7 Amino Acids |
| Fragment Origin | Thymosin Beta-4 (Residues 17–23) |
| Net Peptide Content | 10 mg per vial |
| Form | Lyophilized Research-Grade Powder |
| Intended Use | Laboratory & In-Vitro Research Only |
Important Research Note
TB-500 (Fragment 17–23) is chemically distinct from full-length
Thymosin Beta-4. Researchers should verify peptide identity and
fragment specification prior to experimental use, as nomenclature may vary
across suppliers.
Research Overview
In experimental and preclinical research environments, TB-500 is examined
within laboratory systems focused on peptide signaling behavior, molecular
interaction modeling, and cytoskeletal research frameworks. All studies are
conducted strictly within non-clinical, in-vitro research systems designed
for scientific investigation only.
Key Research Focus Areas
- Peptide-mediated signaling pathway research
- Actin-associated molecular interaction studies
- Peptide fragment stability analysis
- Biochemical pathway investigation
- In-vitro experimental peptide research
All information associated with TB-500 is derived from experimental and
preclinical research contexts only. No claims are made regarding medical,
therapeutic, cosmetic, or clinical outcomes.
Reviews
There are no reviews yet.